These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 26141799)

  • 1. Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
    Lue JK; Amengual JE; O'Connor OA
    Curr Oncol Rep; 2015 Sep; 17(9):40. PubMed ID: 26141799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.
    Hassler MR; Schiefer AI; Egger G
    Epigenomics; 2013 Aug; 5(4):397-415. PubMed ID: 23895653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Hodgkin's lymphoma: the old and the new.
    Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
    Maharaj L; Marson CM; Middleton BJ; Rioja AS; Perry J; Oakervee H; Cavenagh J; Joel SP; Popat R
    Br J Haematol; 2013 Oct; 163(1):135-9. PubMed ID: 23834265
    [No Abstract]   [Full Text] [Related]  

  • 6. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
    Watanabe T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
    Cang S; Ma Y; Liu D
    J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we use epigenetics to prime chemoresistant lymphomas?
    Amengual JE
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):85-94. PubMed ID: 33275728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic drugs take on cancer.
    Kaiser J
    Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
    [No Abstract]   [Full Text] [Related]  

  • 10. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Options for Aggressive T-Cell Lymphomas.
    Lue JK; Kress A; Amengual JE
    Curr Hematol Malig Rep; 2017 Aug; 12(4):269-281. PubMed ID: 28573497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Histone deacetylase inhibitors in the treatment of hematological malignancies].
    Lemal R; Ravinet A; Moluçon-Chabrot C; Bay JO; Guièze R
    Bull Cancer; 2011 Aug; 98(8):867-78. PubMed ID: 21827981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics.
    Duan YT; Sangani CB; Liu W; Soni KV; Yao Y
    Curr Top Med Chem; 2019; 19(12):972-994. PubMed ID: 31161992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy.
    Lu Y; Chan YT; Tan HY; Li S; Wang N; Feng Y
    Mol Cancer; 2020 Apr; 19(1):79. PubMed ID: 32340605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
    Ma H; O'Connor OA; Marchi E
    Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
    Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
    Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of epigenetic therapy in multiple myeloma.
    Smith EM; Boyd K; Davies FE
    Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.